Keratosis, Actinic Clinical Trial
Official title:
Pivotal Study to Assess the Clinical Efficacy and Safety of Microwave Treatment for Actinic Keratosis
NCT number | NCT05636800 |
Other study ID # | EMBAK2 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 18, 2023 |
Est. completion date | April 24, 2024 |
This is a randomized, controlled, multi-center trial in subjects diagnosed with Actinic Keratosis (AK) where each subject serves as their own control. The trial will be conducted at 2 sites, one in Germany and one in the United States. Approximately 60 subjects will be randomized to ensure 51 subjects complete the study.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 24, 2024 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Age 18-85 years inclusive (EU); 22-85 years inclusive (US). 4. AK lesions for randomization in this study: Clinical diagnosis by a dermatologist of precancerous Actinic Keratosis. 5. Cutaneous location. 6. 10, 12 or 14 distinct AK lesions (3-6mm in diameter inclusive), for randomization in this study, located on the subjects' scalp or hands (AK lesions on the scalp and hands for randomization cannot be mixed). - There must be at least 2 AK lesions on the left and right side of the scalp or left and right hand. - An even number of distinct AK lesions (10, 12 or 14) are to be selected. - The maximum possible number of available distinct AK lesions should be selected (10, 12 or 14). - The subject may present with any number of AK lesions, however only 10, 12 or 14 distinct AK lesions will be selected for randomization. For example, if a subject presents with 21 AK lesions, an even number of distinct AK lesions are to be selected (i.e. 14 distinct AK lesions with at least 2 distinct AK lesions on the left and right side of the scalp or left and right hand). 7. If currently receiving treatment for Actinic Keratosis, agree to stop their current medication for at least 28 days prior to the start of study treatment. 8. Agrees to refrain from using any other Actinic Keratosis products or treatments during the study period, unless specified by the Investigator. 9. Agrees to refrain from using any topical metallic or ionic treatment (e.g., aluminum chloride, silver nitrate, zinc oxide) during the study period. 10. Free of any disease state or condition which, in the investigator's opinion, could impair evaluation of AK or could expose the subject to an unacceptable risk by study participation. 11. Able to perform study assessments. Exclusion Criteria: 1. AK lesions at potential treatment sites on lip, nose crease, near eyes or ear. 2. Confluent AK associated with field change at potential treatment sites. 3. Fewer than 2 AK lesions on the left and right side of the scalp or left and right hand. 4. AK lesions at potential treatment sites assessed as clinically ambiguous. 5. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices. 6. Metal implants at site of treatment. 7. Known allergy or intolerance to microwave therapy. 8. Unstable co-morbidities (cardiovascular disease, active malignancy, vasculopathy, inflammatory arthritis). 9. Previous history of skin cancer in the study treatment or observation area. 10. Previous history of squamous cell carcinoma (SCC) or keratoacanthoma (KA) in any location. 11. Pregnancy or breast feeding. 12. Participating in another interventional study or have done so within the last 30 days. 13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures. 14. Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions. 15. Peripheral neuropathy. 16. Subject who is immunosuppressed (organ transplant recipients, hematologic malignancies, HIV). 17. Subject who has had any topical metallic or ionic treatment (e.g, aluminum chloride, silver nitrate, zinc oxide) within the last 6 months at potential treatment sites. 18. Subjects with AK on the scalp and who have hearing aid(s) and are unable or unwilling to remove hearing aids prior to microwave treatment. |
Country | Name | City | State |
---|---|---|---|
Germany | Centroderm GmbH | Wuppertal | |
United States | Miami Dermatology and Laser Institute | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Blackwell Device Consulting | Emblation Limited |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects with treatment success of Actinic Keratosis at 2 months following Swift Microwave treatment. | Definition:
Treatment Success: complete clearance of =75% Actinic Keratosis lesions treated per subject, i.e., at least 75% of the AK lesions treated are fully cleared (not partially cleared). |
2 months post first treatment | |
Secondary | Proportion of subjects with treatment success of Actinic Keratosis following Swift Microwave treatment. | 4 and 6 months post first treatment | ||
Secondary | Proportion of subjects with 100% clearance of Actinic Keratosis following Swift Microwave treatment | 2, 4 and 6 months post first treatment | ||
Secondary | Percentage of Actinic Keratosis lesions cleared across all study lesions following Swift Microwave treatment | 2, 4 and 6 months post first treatment | ||
Secondary | OCT Analysis as assessed by an AK Classification System | AK Lesions classified as Not Present, AK I (Grade I mild), AK II (Grade II, moderate) or AK III (Grade III severe) | Baseline and 2, 4 and 6 months post first treatment | |
Secondary | Proportion of subjects with reoccurrence of any Actinic Keratosis lesions at 6 months, as classified by the blinded site investigator. The subject's AK lesion must be classified as completely resolved at 2 months to be considered a reoccurrence. | 6 months post first treatment | ||
Secondary | Level of pain during treatment using a severity scale | The subject is asked to rate the worst pain experienced during treatment as None, Mild, Moderate or Severe | Treatment 1 (Day 0), Treatment 2 (Day 28) | |
Secondary | Level of pain after treatment using a severity scale | The subject is asked to rate the worst pain experienced during the 10 minute period after treatment is completed as None, Mild, Moderate or Severe | Treatment 1 (Day 0), Treatment 2 (Day 28) | |
Secondary | Duration of pain after treatment using a time period scale | For subjects who experienced pain after treatment, the subject is asked to rate the duration of pain experienced during the 10 minute period after treatment using the following time period scales: a few seconds, up to 1 minute, up to 2 minutes, up to 3 minutes, Still Sore. | Treatment 1 (Day 0), Treatment 2 (Day 28) | |
Secondary | Difference in cosmetic outcomes between treated and non-treated Actinic Keratosis as classified by the independent blinded assessors using a grading system | Photographs of each treated and non-treated AK lesion will be assessed by the independent blinded assessors for cosmetic outcome as "excellent" (slight redness or pigmentation change), "good" (moderate redness or pigmentation change), "fair" (slight-to-moderate scarring, atrophy or induration), or "poor" (extensive scarring, atrophy or induration). Each assessment compares the photos taken at the current visit against the photos taken at the previous visit. The assessments by each independent blinded assessor is recorded separately. | 2, 4 and 6 months post first treatment | |
Secondary | Severity and occurrence of Adverse Events | Up to 12 months post first treatment | ||
Secondary | Evaluation of Patient Reported Outcome (PRO) at baseline and 6 months post first treatment using a rating scale | At Baseline, the subject will be asked to rate how their AK lesions affect their daily activities, lifestyle and mood as: none, mild, moderate and severe.
At 6-months post first treatment, the subject will be asked to rate how their daily activities, lifestyle and mood are now affected, when compared to before study treatment as: significantly better, better, unchanged, worse, significantly worse. The results at baseline and at 6 months post first treatment will be evaluated. |
Baseline and 6 months post first treatment | |
Secondary | Evaluation of Quality of Life (QoL) questionnaires at baseline and 6 months post first treatment using the Dermatology Life Quality Index (DLQI) questionnaire | The DLQI questionnaire measures how the AK lesions have affected the subject's life over the past week. The score at baseline and at 6 months post first treatment will be evaluated. | Baseline and 6 months post first treatment | |
Secondary | Evaluation of Cosmetic Outcome at 6 months post first treatment using a rating scale | The subject will be asked to rate the AK lesions that were treated compared to before treatment as: significantly better, better, unchanged, worse, significantly worse. | 6 months post first treatment | |
Secondary | Long term follow-up of subjects with reoccurrence at 12 months as classified by the blinded site investigator | 12 months post first treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03076892 -
Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS
|
N/A | |
Terminated |
NCT03076918 -
Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy
|
N/A | |
Completed |
NCT05356572 -
A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin
|
N/A | |
Recruiting |
NCT05387525 -
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
|
Phase 4 | |
Completed |
NCT02594644 -
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
|
N/A | |
Active, not recruiting |
NCT02281682 -
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
|
Phase 4 | |
Completed |
NCT01458587 -
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
|
Phase 2 | |
Completed |
NCT05260073 -
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
|
||
Active, not recruiting |
NCT06014697 -
OCT and Invasion in Cutaneous Skin Lesions
|
||
Completed |
NCT05279131 -
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT05481073 -
UV Sensor in Patients With Actinic Keratosis
|
||
Completed |
NCT03697590 -
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
|
Phase 4 | |
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Completed |
NCT02628236 -
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
|
Phase 2 | |
Recruiting |
NCT06135415 -
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT02644187 -
Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
|
N/A | |
Completed |
NCT02281136 -
MUSE Study of Levulan Kerastick
|
Phase 2 | |
Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
Terminated |
NCT04269395 -
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
|
Phase 3 |